However, the on-target and off-target aberrations can co-occur within the same tumor and co-exist with EGFR tertiary mutations that arise from the complexity and heterogeneity of cancer evolution driven by EGFR TKI treatment [17,20]. This evidence concerns the gene EGFR and cancer.